bioAffinity Technologies Inc. announced a validation study with Brooke Army Medical Center to evaluate the CyPath Lung noninvasive early detection lung cancer test using sputum samples collected via tracheal and bronchial deep suctioning during clinical procedures. The study is expected to enroll approximately 30 to 50 patients undergoing routine suctioning, with results expected by mid-year 2026; results have not yet been presented. The company said the study aims to expand sample collection options beyond its standard at-home sputum collection protocol.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.